Source: Annual Congress 2010 - COPD: treatment and monitoring
Disease area: Airway diseases

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is commonly associated with cardiovascular comorbidity and this association may impact reciprocally on disease morbidity and mortality.
Statins and angiotensin-converting enzyme inhibitors (ACEi) are used for their effects on cardiovascular mortality reduction, but little is known on their effects on infective exacerbations of COPD.
Aims: To measure and correlate the use of statins, ACEi and hospital length of stay during COPD exacerbations.
Method: We conducted a retrospective analysis on all COPD exacerbative admissions in 2009 in a district general hospital in London.
Length of stay was measured from an inpatient database, and the use of statins and ACEi were collected from electronic discharge summaries.
Results: We identified 478 admissions (pertaining to 352 patients) specifically for COPD exacerbations. The median age of the patients was 73 years and 60.2% were males. The median admission time was 5 days. A higher proportion of patients with an admission of more than 5 days had concomitant prescriptions for statins and ACEi (43.5% and 33.3% respectively as compared with 34.4% and 28.3% for patients with an admission of ≤ 5 days).

Results

Length of stay	<5 days	>5 days
Patients on statins	34.4%	43.5%
Patients on ACEi	28.3%	33.3%

Conclusion: The use of statins and ACEi was higher in patients who required longer admissions for their COPD exacerbations. These findings may reflect disease severity and the presence of cardiac comorbidities, rather than an effect of statins and ACEi on COPD exacerbations.

Rating:

Share or cite this content

Citations should be made in the following way:
B. Jayaraman, D. Cook, L. O‘Halloran, T. Toma (London, United Kingdom). Correlation between the use of statins and ACE inhibitors with the length of hospitalization for COPD exacerbations. Eur Respir J 2010; 36: Suppl. 54, 1325

Member's Comments

No comment yet.

Related content which might interest you: Statins and outcome of COPD patients after hospitalization for COPD exacerbations Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 No impact of statins on time to first COPD exacerbation or all-cause mortality Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Evaluation of costs of inhospital treatment of COPD exacerbations Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 The direct costs of exacerbations in COPD and the effect of cilomilast treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Association of COPD inhaled  medication adherence with hospitalization for acute exacerbation of COPD (AECOPD) Source: International Congress 2017 – COPD management Year: 2017 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Statin use is associated with reduced mortality in COPD Source: Eur Respir J 2007; 29: 279-283 Year: 2007 Effect of long-term angiotensin-converting factor inhibitors on breathing function and hemorheology indices in patients with tuberculosis and COPD Source: Eur Respir J 2001; 18: Suppl. 33, 306s Year: 2001 Recommendations for bronchodilators and PDE4 inhibitors for prevention of exacerbations of COPD Source: International Congress 2017 – Treatment and prevention of COPD exacerbation Year: 2017 Pharmacologic treatment of exacerbations of COPD Source: International Congress 2016 – Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society (ERS/ATS) guideline Year: 2016 Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Patterns of symptom change measured using the EXACT diary associated with prescription of corticosteroids or antibiotics in COPD exacerbations Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018